BioChem Pharma's first-half results:
This article was originally published in Clinica
BioChem Pharma, the Canadian target of much takeover speculation in recent weeks, has reported sales of Can$93.8 million ($69 million) in the first half, up from Can$39.5 million last year, supported by its acquisition in 1994 of Serono Diagnostics. BioChem's net loss fell to Can$3.3 million compared with Can$4.6 million. BioChem has denied rumours of a takeover approach from UK-based Glaxo Wellcome (see Clinica No 668, p 17).
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.